Ka Koram1, L Quaye, B Abuaku. 1. Department of Epidemiology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, P. O. Box LG 581, Legon.
Abstract
BACKGROUND: In 2005, following several years of declining efficacy of chloroquine, the Ministry of Health recommended the use of Amodiaquine/Artesunate combination therapy for the treatment of uncomplicated malaria. A system of continuous monitoring of therapeutic responses has been established in 10 district hospitals across the country. The data gathered will enable National Malaria Control Programme (NMCP) to respond to changes in the efficacy of the new treatment in a timely manner. OBJECTIVES: To determine the 28 day therapeutic efficacy of Amodiaquine/Artesunate (AQ/AS) combination treatment in children with uncomplicated malaria in Ghana. METHODS: Children aged 6 - 59 months attending clinic with signs/symptoms of uncomplicated malaria at 9 district hospitals (3 in each of the 3 eco-epidemiological zones of the country) were eligible for enrolment. Enrolled children were followed up after treatment for a total of 28 days to record the clinical and parasitological resolution of their malaria episode as well as any adverse drug reactions. RESULTS: Treatment resulted in rapid and complete cure in almost all the children; 99.3% 14 days after treatment and 93.0%, 28 days after treatment. The majority of treatment failures on D28 were seen in the 3 sites located in the forest zones (Sunyani, Bekwai and Begoro). There was no case of Early Treatment Failure at both D14 and D28 assessments. Adverse events (AE's) were minimal, less than 4%, with the most common complaint being vomiting. CONCLUSION: AQ/AS combination for uncomplicated malaria is efficacious and safe in children less than 5 years.
BACKGROUND: In 2005, following several years of declining efficacy of chloroquine, the Ministry of Health recommended the use of Amodiaquine/Artesunate combination therapy for the treatment of uncomplicated malaria. A system of continuous monitoring of therapeutic responses has been established in 10 district hospitals across the country. The data gathered will enable National Malaria Control Programme (NMCP) to respond to changes in the efficacy of the new treatment in a timely manner. OBJECTIVES: To determine the 28 day therapeutic efficacy of Amodiaquine/Artesunate (AQ/AS) combination treatment in children with uncomplicated malaria in Ghana. METHODS:Children aged 6 - 59 months attending clinic with signs/symptoms of uncomplicated malaria at 9 district hospitals (3 in each of the 3 eco-epidemiological zones of the country) were eligible for enrolment. Enrolled children were followed up after treatment for a total of 28 days to record the clinical and parasitological resolution of their malaria episodeas well as any adverse drug reactions. RESULTS: Treatment resulted in rapid and complete cure in almost all the children; 99.3% 14 days after treatment and 93.0%, 28 days after treatment. The majority of treatment failures on D28 were seen in the 3 sites located in the forest zones (Sunyani, Bekwai and Begoro). There was no case of Early Treatment Failure at both D14 and D28 assessments. Adverse events (AE's) were minimal, less than 4%, with the most common complaint being vomiting. CONCLUSION:AQ/AS combination for uncomplicated malaria is efficacious and safe in children less than 5 years.
Authors: A Sowunmi; A I Ayede; A G Falade; V N Ndikum; C O Sowunmi; A A Adedeji; C O Falade; T C Happi; A M Oduola Journal: Ann Trop Med Parasitol Date: 2001-09
Authors: E Amukoye; P A Winstanley; W M Watkins; R W Snow; J Hatcher; M Mosobo; E Ngumbao; B Lowe; M Ton; G Minyiri; K Marsh Journal: Antimicrob Agents Chemother Date: 1997-10 Impact factor: 5.191
Authors: M Adjuik; P Agnamey; A Babiker; S Borrmann; P Brasseur; M Cisse; F Cobelens; S Diallo; J F Faucher; P Garner; S Gikunda; P G Kremsner; S Krishna; B Lell; M Loolpapit; P B Matsiegui; M A Missinou; J Mwanza; F Ntoumi; P Olliaro; P Osimbo; P Rezbach; E Some; W R J Taylor Journal: Lancet Date: 2002-04-20 Impact factor: 79.321
Authors: J F Trape; G Pison; M P Preziosi; C Enel; A Desgrées du Loû; V Delaunay; B Samb; E Lagarde; J F Molez; F Simondon Journal: C R Acad Sci III Date: 1998-08
Authors: Marie Helleberg; Bamenla Q Goka; Bartholomew D Akanmori; George Obeng-Adjei; Onike Rodriques; Jorgen A L Kurtzhals Journal: Malar J Date: 2005-12-01 Impact factor: 2.979
Authors: Sena A Matrevi; Philip Opoku-Agyeman; Neils B Quashie; Selassie Bruku; Benjamin Abuaku; Kwadwo A Koram; Anne Fox; Andrew Letizia; Nancy O Duah-Quashie Journal: Antimicrob Agents Chemother Date: 2019-10-22 Impact factor: 5.191
Authors: Benjamin K Abuaku; Benedicta A Mensah; Michael F Ofori; James Myers-Hansen; Abigail N Derkyi-Kwarteng; Felicia Essilfie; Moses Dokurugu; Emmanuel Amoakoh; Kwadwo A Koram; Anita Ghansah Journal: Am J Trop Med Hyg Date: 2017-07-27 Impact factor: 2.345
Authors: Issiaka Soulama; Jude D Bigoga; Magatte Ndiaye; Edith C Bougouma; Josephine Quagraine; Prisca N Casimiro; Timothy T Stedman; Sodiomon B Sirima Journal: Am J Trop Med Hyg Date: 2011-02 Impact factor: 2.345
Authors: Donne Kofi Ameme; Edwin Andrews Afari; Kofi Mensah Nyarko; Keziah Laurencia Malm; Samuel Sackey; Fred Wurapa Journal: Pan Afr Med J Date: 2014-12-10
Authors: Nancy O Duah; Sena A Matrevi; Dziedzom K de Souza; Daniel D Binnah; Mary M Tamakloe; Vera S Opoku; Christiana O Onwona; Charles A Narh; Neils B Quashie; Benjamin Abuaku; Christopher Duplessis; Karl C Kronmann; Kwadwo A Koram Journal: Malar J Date: 2013-10-30 Impact factor: 2.979